FOLLOWUS
Systematic review of β-Elemene injection as adjunctive treatment for lung cancer
- Chinese Journal of Integrative Medicine Vol. 18, Issue 11, Pages: 813-823(2012)
- Affiliations：
1. School of Public Health and Family Medicine, Capital Medical University,Beijing,China
2. Guang’an Men Hospital, China Academy of Chinese Medical Sciences,Beijing,China
3. Institute of Basic Research in Chinical Medicine, China Academy of Chinese Medical Sciences,Beijing,China
4. Department of Neurology, Beijing Tiantan Hospital, Capital Medical University,Beijing,China
5. Biomedicine and Health Research Center, Hangzhou Normal University,Hangzhou,China
- Author bio：
- Funds：
DOI：10.1007/s11655-012-1271-9
CLC：Published：2012，
Published Online：20 October 2012，
Scan for full text
Wang, B., Peng, Xx., Sun, R. et al. Systematic review of β-Elemene injection as adjunctive treatment for lung cancer., Chin. J. Integr. Med. 18, 813–823 (2012). https://doi.org/10.1007/s11655-012-1271-9
Bin Wang, Xiao-xia Peng, Rao Sun, et al. Systematic review of β-Elemene injection as adjunctive treatment for lung cancer. [J]. Chinese Journal of Integrative Medicine 18(11):813-823(2012)
Wang, B., Peng, Xx., Sun, R. et al. Systematic review of β-Elemene injection as adjunctive treatment for lung cancer., Chin. J. Integr. Med. 18, 813–823 (2012). https://doi.org/10.1007/s11655-012-1271-9 DOI：
Bin Wang, Xiao-xia Peng, Rao Sun, et al. Systematic review of β-Elemene injection as adjunctive treatment for lung cancer. [J]. Chinese Journal of Integrative Medicine 18(11):813-823(2012) DOI： 10.1007/s11655-012-1271-9.
摘要
To evaluate the effectiveness and safety of β-elemene Injection as an adjunctive treatment for lung cancer by systematic review. We retrieved randomized controlled clinical trials related to the use of β-elemene Injection as an adjunctive treatment for lung cancer from Chinese Biomedical (CBMweb)
Chinese Medical Current Content (CMCC)
China National Knowledge Infrastructure (CNKI)
ChinaInfo
Cochrane Central Register of Controlled Trials; MEDLINE
EMBASE
OVID and TCMLARS. We also referred to an unpublished conference proceeding titled Clinical Use and Basic: Elemene Injection. We then divided the studies into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) subgroups by RevMan 5.1 software. A total of 21 source documents (1
467 patients) matched pre-specified criteria for determining the effectiveness and safety of β-elemene Injection as an adjunctive treatment for lung cancer. Five studies involving 285 NSCLC patients reported a higher 24-month survival rate (39.09%) with the adjunctive treatment than with chemotherapy alone (26.17%; RR
1.51; 95% CI
1.03 to 2.21). Four studies involving 445 patients reported that the increased probability for improved performance status for patients treated with elemene-based combinations was higher than that of patients treated with chemotherapy alone (RR
1.82; 95% CI
1.45 to 2.29). The results from a subgroup analysis on 12 studies involving 974 NSCLC patients and 9 studies involving 593 patients with both SCLC and NSCLC showed that the tumor control rate for NSCLC improved more in the elemene-based combinations treatment group (78.70%) than in the chemotherapy alone control group (71.31%; RR
1.06; 95% CI
1.00 to 1.12). The tumor response rate for NSCLC also improved more among patients treated with elemenebased combinations (50.71%) than among patients treated with chemotherapy alone (38.04%; RR
1.34; 95%CI
1.17 to 1.54). In addition
the main adverse reaction to β-elemene Injection was phlebitis
but usually only to a mild degree. An Egger’s test showed no publication bias in our study (P=0.7030). The effectiveness of chemotherapy for the treatment of lung cancer may improve when combined with β-elemene injection as an adjunctive treatment. The combined treatment can result in an improved quality of life and prolonged survival. However
these results require confirmation by rigorously controlled trials.
Abstract
To evaluate the effectiveness and safety of β-elemene Injection as an adjunctive treatment for lung cancer by systematic review. We retrieved randomized controlled clinical trials related to the use of β-elemene Injection as an adjunctive treatment for lung cancer from Chinese Biomedical (CBMweb)
Chinese Medical Current Content (CMCC)
China National Knowledge Infrastructure (CNKI)
ChinaInfo
Cochrane Central Register of Controlled Trials; MEDLINE
EMBASE
OVID and TCMLARS. We also referred to an unpublished conference proceeding titled Clinical Use and Basic: Elemene Injection. We then divided the studies into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) subgroups by RevMan 5.1 software. A total of 21 source documents (1
467 patients) matched pre-specified criteria for determining the effectiveness and safety of β-elemene Injection as an adjunctive treatment for lung cancer. Five studies involving 285 NSCLC patients reported a higher 24-month survival rate (39.09%) with the adjunctive treatment than with chemotherapy alone (26.17%; RR
1.51; 95% CI
1.03 to 2.21). Four studies involving 445 patients reported that the increased probability for improved performance status for patients treated with elemene-based combinations was higher than that of patients treated with chemotherapy alone (RR
1.82; 95% CI
1.45 to 2.29). The results from a subgroup analysis on 12 studies involving 974 NSCLC patients and 9 studies involving 593 patients with both SCLC and NSCLC showed that the tumor control rate for NSCLC improved more in the elemene-based combinations treatment group (78.70%) than in the chemotherapy alone control group (71.31%; RR
1.06; 95% CI
1.00 to 1.12). The tumor response rate for NSCLC also improved more among patients treated with elemenebased combinations (50.71%) than among patients treated with chemotherapy alone (38.04%; RR
1.34; 95%CI
1.17 to 1.54). In addition
the main adverse reaction to β-elemene Injection was phlebitis
but usually only to a mild degree. An Egger’s test showed no publication bias in our study (P=0.7030). The effectiveness of chemotherapy for the treatment of lung cancer may improve when combined with β-elemene injection as an adjunctive treatment. The combined treatment can result in an improved quality of life and prolonged survival. However
these results require confirmation by rigorously controlled trials.
关键词
β-elemene injectionlung cancersystematic review
Keywords
β-elemene injectionlung cancersystematic review
references
He J, Gu D, Wu X, Reynolds K, Duan XF, Yao CH, et al. Major causes of death among men and women in China. New Engl J Med 2005;353:1124–1134.
Li QQ, Wang G, Zhang M, Cuff CF, Huang L, Reed E. Beta-elemene, a novel plant-derived antineoplastic agent, increases cisplatin chemosensitivity of lung tumor cells by triggering apoptosis. Oncol Rep 2009;22:161–170.
McCulloch M, See C, Shu XJ, Broffman M, Kramer A, Fan WY, et al. Astragalus-based Chinese herbs and platinumbased chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. J Clin Oncol 2006;24:419–430.
Li QQ, Wang G, Reed E, Huang L, Cuff CF. Evaluation of cisplatin in combination with beta-elemene as a regimen for prostate cancer chemotherapy. Basic Clin Pharmacol Toxicol 2010 Apr 23. [Epub ahead of print].
Chen WX, Lu Y, Wu JM, Gao M, Wang AY, Xu B. Betaelemene inhibits melanoma growth and metastasis via suppressing vascular endothelial growth factor-mediated angiogenesis. Cancer Chemother Pharmacol 2010 Jun 19. [Epub ahead of print].
Qiu J, Zhang X, Luo M. Beta-Elemene piperazine derivatives induce apoptosis in human leukemia cells through downregulation of c-FLIP and generation of ROS. PLoS One 2011; 6: e15843. doi:10.1371/journal.pone.0015843.
Yaoa YQ, Dingb X, Jiab YC, Huangb CX, Wangb YZ, Xua YH. Anti-tumor effect of β-elemene in glioblastoma cells depends on p38 MAPK activation. Cancer Letter 2008;264:127–134.
Peng X, Zhao YL, Liang XY, Wu LJ, Cui SQ, Guo AM, et al. Assessing the quality of RCTs on the effect of β-elemene, one ingredient of a Chinese herb, against malignant tumors. Contemp Clin Trials 2006;27:70–82.
Zhao YL, Peng X, Wang YD, Cui SQ. Evaluation of efficacy and safety of Elemene Injection in treating lung cancer. Chin J Evidence-Based Med (Chin) 2005;5:216–228.
Dong R, Chen X, Wu T, Liu GJ. Elemene for the treatment of lung cancer. Cochrane Database of Systematic Reviews 2007, Issue 4. Art. No.: CD006054. DOI: 10.1002/14651858. CD006054.pub2.
Higgins JPT, Green S, eds. Locating and selecting studies for reviews. Cochrane Handbook for Systematic Reviews of Interventions 4.2 [updated May 2005]; Section 5. The Cochrane Library, Issue 3. Chichester, UK: John Wiley & Sons, Ltd, 2005.
Sutton AJ, Abrams KR, Jones DR. Methods for metaanalysis in medical research. Chichester, New York: John Wiley & Sons, Inc., 2000.
Qin SK, Qian J, Wang L, Yang AZ, Liu WH. Clinical observation of Elemene emulsion combined with chemotherapy against primary lung cancer. Oncol Prev Cure Res (Chin) 1998;25:58–60.
Liu JF. Clinical observation of Elemene combined with MVP against middle and terminal lung cancer. J Henan Oncol (Chin) 2000;13:434–435.
Zhang MX. Clinical trials of Elemene emulsion sensitizing effect of chemotherapy against lung cancer. Anhui Med J (Chin) 1997;18:42.
Shi XL, Fan ZZ, Sun Y. Clinical study of integrated therapy of traditional Chinese and Western medicine in treating non-small cell lung cancer in elderly. Shanghai J Tradit Chin Med (Chin) 2006;40:27–28.
Zhou D. Randomized comparison of combination of Elemene Emulsion and VP vs VP in treating end-stage non-small cell lung cancer. Chin J Clin Oncol (Chin) 2001;28:470–471.
Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomized clinical trials. Stat Med 1991;10:1665–1677
Chen YP, Zhuang WB, Liu YC. Clinical efficacy of combination of elemene and DC regimen in treating endstage non-small cell lung cancer. Shandong Med J (Chin) 2008;48:54–55.
Zhou L, Liu FQ, Zhang HM, Zhou ZJ. Clinical efficacy and safety of combination of elemene and chemotherapy in treating advanced non-small cell lung cancer. Pharmacol Clin Chin Mater Med (Chin) 2009;25:113–115.
Chen YL, Yang KH. CONSORT 2010. Lancet 2010;376:230.
Catherine Hewitt, Seokyung Hahn, David J Torgerson, Judith Watson, J Martin Bland. Adequacy and reporting of allocation concealment: review of recent trials published in four general medical journals. BMJ 2005;330:1057–1058.
Lam CW, James JT, McCluskey R, Hunter RL. Hunter pulmonary toxicity of single-wall carbon nanotubes in mice 7 and 90 days after intratracheal instillation. Toxicol Sci 2004;77:126–134.
Wang J, Hu J. Clinical observation of combination of elemene emulsion and CE in treating non-small cell lung cancer. Chin J Clin Oncol (Chin) 2000;27:312–313.
Tan S, Xue YB, Jiang GL. Combination of elemene emulsion and EP regimen in treating end-stage non-small cell lung cancer. Zhejiang J Integr Tradit Chin West Med (Chin) 2002;12:215–216.
Lu LQ, Liu ZJ, Chen FH, Zai YC. Study of elemene emulsion in the therapy for lung cancer. Zhejiang Oncol (Chin) 1996;2:185–186.
Yuan HX. Clinical observation of combination of elemene emulsion and NP regimen in treating end-stage non-small cell lung cancer. Chin J Clin Med Pract (Chin) 2003;15:60–61.
Li X, Xu SX, Shang GY. Comparison of elemene and general medicine against lung cancer by double artery injection. Chin J Clin Oncol (Chin) 1998;25:35–39.
Yang CS, Zhang J. Clinical study of elemene emulsion and EP regimen in treating end-stage lung cancer. Chin J Clin Oncol (Chin) 1998;25:71–72.
Mou L, Ding ZJ. Effect analysis of elemene associated with MVP against middle and terminal lung cancer. Chin J Clin Oncol (Chin) 1998;25:73–74.
Liang C, Fan YZ. Analysis of the efficacy of combination of elemene emulsion and chemotherapy in treating advanced lung cancer. Chin J Clin Oncol (Chin) 1998;25:47–49.
Zheng H, Yao FX, Wang LP, Gong XY, Li DL. Clinical observation of chemotherapy in 146 cases of lung cancer. Chin J Clin Oncol (Chin) 1998;25:42–43.
Chen NJ, Li H, Tan SS, Yang YF. Clinical observation of combination of weekly Docetaxel and elemene emulsion in treating 68 case of elderly end-stage non-small cell lung cancer. Chin J Clin Oncol (Chin) 2005;32:896–897.
Shan SL. Comparison of combination of elemene emulsion and chemotherapy vs combination chemotherapy in treating end-stage malignancies. Chin J Clin Oncol (Chin) 1998;25:115–116.
Tian L, Cao YA, Peng CS, Zhao YZ. Clinical observation of combination of elemene emulsion and chemotherapy in treating end-stage non-small cell lung cancer. J Chin Clin Med (Chin) 2009;16:725–727.
Yang ZY, Wang LN. Clinical observation of combination of Elemene Injection and DP regimen in treating end-stage non-small cell lung cancer in elderly. J Tradit Chin Med Univ Hunan (Chin) 2009;29:5–7.
Chu DJ, Guo SG, Yao DE. To study elemene emulsion, gemcitabine, and cisplatin in the treatment of advanced non-small cell lung cancer. Chin J Clin Med (Chin) 2010;17:491–494.
Wang L, Shen F. Elemene emulsion combined with NP chemotherapy in the treatment of advanced NSCLC patients. China Oncol (Chin) 2010;20:547–550.
0
Views
101
Downloads
27
CSCD
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
- Tel：010-62886827, 62877592 Fax：010-62874291
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
